Translating personalized medicine using new genetic technologies in clinical practice: the ethical issues

Personalized Medicine

Volumn 11, Issue 2, 2014, Pages 211-222

  Ormond, Kelly E ^a,b   Cho, Mildred K ^b  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ethics; genetics; genomics; personalized medicine; translation

Indexed keywords

ACCESS TO INFORMATION; ACCURACY; CLINICAL PRACTICE; DATA OWNERSHIP; DATA SHARING; DNA SEQUENCE; GENE TECHNOLOGY; GENETIC PRIVACY; GENETIC SCREENING; GENOME ANALYSIS; HUMAN; INFORMATION PROCESSING; INFORMED CONSENT; MEDICAL ETHICS; PATENT; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; SEQUENCE ANALYSIS;

EID: 84899481029     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.13.104     Document Type: Review

References (111)

1. Moeschler J, Shevell M. Clinical genetic evaluation of the child with mental retardation or developmental delays. Pediatrics 117, 2304 (2006
2. Michaelson D, Shevell M, Sherr E et al. Evidence Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 77, 1629-1635 (2011
3. Miles J. Autism spectrum disorders-A genetics review. Genet. Med. 13, 278-294 (2011
4. Yang Y, Muzny D, Reid J et al. Clinical whole-exome sequencing for the diagnosis of Mendelian disorders. N. Engl. J. Med. 369(16), 1502-1511 (2013
5. Korf B, Rehm H. New approaches to molecular diagnosis. JAMA 309, 1511-1521 (2013
6. GeneDx. DNA Diagnostic experts.www.genedx.com
7. Ambry Genetics™.http://ambrygen.com/tests
8. Athena Diagnostics®.www.athenadiagnostics.com/content/test-catalog
9. Personal Genome Project.www.personalgenomes.org
10. Srinivasan B, Evans E, Flannick J et al. A universal carrier test for the long tail of Mendelian disease. Reprod. Biomed. Online 21, 537-551 (2010
11. Manning M, Hudgins L. Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities. Genet. Med. 12, 742-745 (2010
12. Annuziata C, Bates S. PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer. F1000 Biol. Reports 2, 10 (2010
13. Clayton EW, Haga S, Kuszler P, Bane E, Shutske K, Burke W. Managing incidental genomic findings: Legal obligations of clinicians. Genet. Med. 15, 624-629 (2013
14. van El CG, Cornel MC, Borry P et al. Whole genome sequnecing in health care: Recommendations of the European Society of Human Genetics. Eur. J. Hum. Genet. 21, 580-584 (2013
15. Jamal S, Yu J-H, Chong J et al. Practices and policies of clinical exome sequencing providers: Analysis and implications. Am. J. Med. Genet. 161A, 935-950 (2013
16. Hannibal M, Buckingham K, Ng S et al. Spectrum of MLL2 (ALR) mutations in 110 cases of Kabuki syndrome. Am. J. Med. Genet. 155A, 1511-1516 (2011
17. McLaughlin H, Sakaguchi R, Liu C et al. Compound heterozygosity for loss-of-function lysyl-TRNA synthetase mutations in a patient with peripheral neuropathy. Am. J. Hum. Genet. 8, 560-566 (2010
18. Ng S, Buckingham K, Lee C et al. Exome sequencing identifies the cause of a mendelian disorder. Nat. Genet. 42, 30-35 (2010
19. Worthey E, Mayer A, Syverson G et al. Making a definitive diagnosis: Successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. Genet. Med. 13, 255-262 (2011
20. Rienhoff HJ, Yeo C, Morissette R et al. A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with marfan and Loeys-Dietz syndrome. Am. J. Med. Genet. Part A 161A(8), 2040-2046 (2013
21. Saunders C, Miller N, Soden S et al. Rapid whole-genome sequencing for genetic disease diagnosis in neonatal intensive care units. Sci. Transl. Med. 4, 154ra135 (2012
22. The Cancer Genome Atlas. Understanding genomics to improve cancer care.http://cancergenome.nih.gov/researchhighlights/perspectives/ levineperspective
23. Ashley E, Butte A, Wheeler M et al. Clinical evaluation incorporating a personal genome. Lancet 375, 1525-1535 (2010
24. Dewey F, Chen R, Cordero S et al. Phased whole-genome genetic risk in a family quartet using a major allele reference sequence. PLoS Genet. 7, e1002280 (2011
25. Hollegaard M, Grauholm J, Nielsen R et al. Archived neonatal dried blood spot samples can be used for accurate whole genome and exome-Targeted next-generation sequencing. Mol. Genet. Metab. 110(1-2), 65-72 (2013
26. Goldenberg A, Dodson D, Davis M, Tarini B. Parents' interest in whole-genome sequencing of newborns. Genet. Med. 16(1), 78-84 (2013
27. Ormond KE, Wheeler MT, Hudgins L et al. Challenges in the clinical application of whole-genome sequencing. Lancet 375(9727), 1749-1751 (2010
28. LAm. HYK, Clark MJ, Chen R et al. Performance comparison of whole-genome sequencing platforms. Nature 30(1), 78-82 (2011
29. O'rawe J, Jiang T, Sun G et al. Low concordance of multiple variant-calling pipelines: Practical implications for exome and genome sequencing. Genome Med. 5, 28 (2013
30. Lohn Z, Adam S, Birch P, Friedman J. Incidental findings from clinical genome-wide sequencing: A review. J. Genet. Couns. doi:10.1007/s10897-013-9604-4 (2013) (Epub ahead of print
31. John Hawks weblog: Palentology, genetics and evolution.http://johnhawks. net/weblog/topics/biotech/testing/fda-dtc-meeting-proceedings-2011.html
32. Berg J, Khoury M, Evans J. Deploying whole genome sequencing in clinical practice and public health: Meeting the challenge one bin at a time. Genet. Med. 13, 499-504 (2011
33. Grove M, Wolpert M, Cho M, Lee S, Ormond K. Assessing views of genetics health professionals toward the return of genomic results. J. Genet. Couns. doi:10.1007/s10897-013-9611-5 (2013) (Epub ahead of print
34. Yu J, Jamal S, Tabor H, Bamshad M. Self-guided management of exome and whole-genome sequencing results: Changing the results return model. Genet. Med. 15(9), 684-690 (2013
35. Lohn Z, Adam S, Birch P, Townsend A, Friedman J. Genetics professionals' perspectives on reporting incidental findings from clinical genome-wide sequencing. Am. J. Med. Genet. 161, 542-549 (2013
36. Green R, Berg J, Berry G et al. Exploring concordance and discordance for return of incidental findings from clinical sequencing. Genet. Med. 14, 405-410 (2012
37. Green R, Berg J, Grody W et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet. Med. 15, 565-574 (2013
38. McGuire A, Joffe S, Koenig B et al. Point-counterpoint. Ethics and genomic incidental findings. Science 340, 1049-1050 (2013
39. Green RC, Lupski JR, Biesecker LG. Reporting genomic sequencing results to ordering clinicians: Incidental, but not exceptional. JAMA 310, 365-366 (2013
40. Wolf S, Annas G, Elias S. Point-counterpoint. Patient autonomy and incidental findings in clinical genomics. Science 340, 1049-1050 (2013
41. Klitzman R, Appelbaum PS, Chung W. Return of secondary genomic findings vs patient autonomy: Implications for medical care. JAMA 310, 369-370 (2013
42. Ross LF, Rothstein MA, Clayton EW. Mandatory extended searches in all genome sequencing: 'incidental findings,' patient autonomy, and shared decision making. JAMA 310, 367-368 (2013
43. Hampel H, Grubs RE, Walton CS et al. Genetic counseling practice analysis. J. Genet. Couns. 18, 05-16 (2009
44. Skirton H, Goldsmith L, Jackson L, Tibben A. Quality in genetic counselling for presymptomatic testing-clinical guidelines for practice across the range of genetic conditions. Eur. J. Hum. Genet. 21, 256-260 (2013
45. Cameron L, Muller C. Psychosocial outcomes after genetic testing. Curr. Opin. Psychiatry 22, 218-223 (2009
46. Elias S, Annas G. Generic consent for genetic screening. N. Engl. J. Med. 330, 1611-1613 (1994
47. Ormond K, Cirino A, Helenowski I, Chisholm R, Wolf W. Assessing the understanding of biobank participants. Am. J. Med. Genet. 149A, 188-198 (2009
48. Sanderson SC, Zinberg R, Horowitz CR et al. Willingness to participate in genomics research and desire for personal results among underrepresented minority patients: A structured interview study. J. Commun. Genet. 4(4), 469-482 (2013
49. Facio F, Eidem H, Fisher T et al. Intentions to receive individual results from whole-genome sequencing among participants in theClinSeq study. Eur. J. Hum. Genet. 21, 261-265 (2013
50. Hodgson J, Gaff C. Enhancing family communication about genetics: Ethical and professional dilemmas. J. Genet. Couns. 22, 16-21 (2013
51. Virtual Mentor: American Medical Association.http://virtualmentor.ama- Assn.org.laneproxy.stanford.edu//2012/08/hlaw1-1208.html
52. Tarasoff v. Regents of the University of California, 131 Cal. Rptr. 14 (Cal. 1976
53. Safer v. Estate of Pack, 677A. 2d 1188 (N.J. Super CT App Div. 1996
54. Watters v White.http://pattersonlaw.ca/PattersonBlogs/ MedicalMalpracticeBlog/tabid/268/EntryId/77/What-To-Say-Do-Doctors-Have-A-Duty- To-Disclose-Confidential-Information.aspx
55. Pate v Threlkel, 661, So 2d 278 (Fla 1995
56. Australian Law Reform Commission. Introduction to the enquiry: Essentially yours. In: The Protection of Human Genetic Information in Australia. Australian Government, Australian Law Reform Commission, Sydney, Australia (1996
57. Ross L, Saal H, David K, Anderson R. Technical report: Ethical and policy issues in genetic testing and screening of children. Genet. Med. 15, 234-245 (2013
58. Michie S, Bobrow M, Marteau TM. Predictive genetic testing in children and adults: A study of emotional impact. J. Med. Genet. 38, 519-526 (2001
59. Codori AM, Zawacki KL, Petersen GM et al. Genetic testing for hereditary colorectal cancer in children: Long-Term psychological effects. Am. J. Med. Genet. A. 116A, 117-128 (2003
60. Paradise J, Andrews L, Holbrook T. Intellectual property. Patents on human genes: An analysis of scope and claims. Science 307(5715), 1566-1567 (2005
61. Jensen K, Murray F. Intellectual property landscape of the human genome. Science 310(5746), 239-240 (2005
62. Rosenfeld J, Mason CE. Pervasive sequence patents cover the entire human genome. Genome Med. 5(3), 27-27 (2013
63. Kepler TB, Crossman C, Cook-Deegan R. Metastasizing patent claims on BRCA1. Genomics 95(5), 312-314 (2010
64. Walsh JP, Cohen WM, Arora A. Science and the law. Working through the patent problem. Science 299(5609), 1021 (2003
65. Blumenthal D, Campbell EG, Anderson MS, Causino N, Louis KS. Withholding research results in academic life science. JAMA 277(15), 1224-1228 (1997
66. Cho MK, Illangasekare S, Weaver MA, Leonard DG, Merz JF. Effects of patents and licenses on the provision of clinical genetic testing services. J. Mol. Diagn 5(1), 3-8 (2003
67. Rabino II. How human geneticists in US view commercialization of the Human Genome Project. Nat. Genet. 29(1), 15-16 (2001
68. Chandrasekharan S, Heaney C, James T, Conover C, Cook-Deegan R. Impact of gene patents and licensing practices on access to genetic testing for cystic fibrosis. Genet. Med. 12, S194-S211 (2010
69. Cook-Deegan R, Derienzo C, Carbone J, Chandrasekharan S, Heaney C, Conover C. Impact of gene patents and licensing practices on access to genetic testing for inherited susceptibility to cancer: Comparing breast and ovarian cancers with colon cancers. Genet. Med. 12, S15-S38 (2010
70. US District Court Southern District of New York. Association of Molecular Pathology v. United States Patent and Trademark Office. US District Court Southern District of New York NY, USA, 1-156 (2010
71. Walsh T, Casadei S, Coats KH et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295(12), 1379-1388 (2006
72. Walsh T, Lee MK, Casadei S et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc. Natl Acad. Sci. USA 107(28), 12629-12633 (2010
73. Anderson A U of Washington debuts targeted sequencing test for mutations in inherited colon cancer genes (2011).www.genomeweb.com/sequencing/u- washington-debuts-Targeted-sequencing-Test-mutations-inherited-colon-cancer-ge
74. Heller MA, Eisenberg R. Can patents deter innovation? The anticommons in biomedical research. Science 280(5364), 698-701 (1998
75. 23andMe.www.23andme.com/health/BRCA-Cancer
76. Ray T 23andMe adds BRCA breast/ovarian cancer testing to service.www.genomeweb.com/dxpgx/23andme-Adds-brca-breastovarian-cancer-Testing- service
77. Biesecker LG. Opportunities and challenges for the integration of massively parallel genomic sequencing into clinical practice: Lessons from the ClinSeq project. Genet. Med. 14(4), 393-398 (2012
78. Schissel A, Merz JF, Cho MK. Survey confirms fears about licensing of genetic tests. Nature 402(6758), 118 (1999
79. International Collaboration for Clinical Genomics.http:// sharingclinicalreports.org
80. Kolata G. DNA project aims to make company's data public. The New York Times, 12th April (2013
81. Check Hayden E. Genetics push for global data-sharing. Nature 498, 16-17 (2013
82. Hogarth S, Javitt G, Melzer D. The current landscape for direct-To-consumer genetic testing: Legal, ethical, and policy issues. Annu. Rev. Genomics Hum. Genet. 9, 161-182 (2008
83. Kaye J. The regulation of direct-To-consumer genetic tests. Hum. Mol. Genet. 17(R2), R180-R183 (2008
84. Kutz G. Testimony Before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives. Direct-To-consumer Genetic Tests: Misleading Test Results Are Further Complicated by Deceptive Marketing and Other Questionable Practices. US Government Accountability Office, DC, USA, 1-33 (2010
85. Presidential Commission for the Study of Bioethical Issues. Privacy and Progress in Whole Genome Sequencing. US Department of Health & Human Services, DC, USA, 1-154 (2012
86. Genetics & Public Policy Center.www.dnapolicy.org/policy.issue.php? action=detail&issuebrief-id=48
87. Borry P, Van Hellemondt RE, Sprumont D et al. Legislation on direct-To-consumer genetic testing in seven European countries. Eur. J. Hum. Genet. 20(7), 715-721 (2012
88. Additional Protocol to the Convention on Human Rights and Biomedicine, concerning Genetic Testing for Health Purposes: Strasbourg, 27.XI.2008.http:// conventions.coe.int/Treaty/en/Treaties/Html/203.htm
89. Lwoff L. Council of Europe adopts protocol on genetic testing for health purposes. Eur. J. Hum. Genet. 17, 374-1377 (2009
90. US FDA: In vitro diagnostics.www.fda.gov/MedicalDevices/ ProductsandMedicalProcedures/InVitroDiagnostics/default.htm
91. Ray T. Amid Chaos, FDA's Gutierrez offers insights on agency's regulatory stance on molecular tests. www.genomeweb.com/clinical-genomics/amid-chaos-fdas- gutierrez-offers-insights-Agencys-regulatory-stance-molecular-Te
92. Council EPaT. Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995 on the protection of individuals with regard to the processing of personal data and on the free movement of such data. Directive 95/46/EC (1995).http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX: 31995L0046:en:HTML
93. European Union. Proposal for a directive of the European Parliament and of the Council on the protection of individuals with regard to the processing of personal data by competent authorities for the purposes of prevention, investigation, detection or prosecution of criminal offences or the execution of criminal penalties, and the free movement of such data. (2012).http://eur-lex. europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:52012PC0010:en:NOT
94. Benitez K, Malin B. Evaluating re-identification risks with respect to the HIPAA privacy rule. BMJ 17(2), 169 (2010
95. Lin Z, Owen AB, Altman RB. Genomic research and human subject privacy. Science 305, 183 (2004
96. Schadt EE, Woo S, Hao K. Bayesian method to predict individual SNP genotypes from gene expression data. Nat. Genet. 44(5), 603-608 (2012
97. Homer N, Szelinger S, Redman M et al. Resolving individuals contributing trace amounts of dna to highly complex mixtures using high-density snp genotyping microarrays. PLoS Genetics 4(8), e1000167 (2008
98. Im HK, Gamazon ER, Nicolae DL, Cox NJ. On sharing quantitative trait GWAS results in an era of multiple-omics data and the limits of genomic privacy. Am. J. Hum. Genet. 90(4), 591-598 (2012
99. Schloissnig S, Arumugam M, Sunagawa S et al. Genomic variation landscape of the human gut microbiome. Nature 493(7430), 45-50 (2012
100. Gymrek M, McGuire AL, Golan D, Halperin E, Erlich Y. Identifying personal genomes by surname inference. Science 339, 321-324 (2012
101. Malin B, Sweeney L. Re-identification of DNA through an automated linkage process. Proc. AMIA Symp. 423-427 (2001
102. Sweeney L. Achieving k-Anonymity: Privacy protection using generalization and suppression. Int. J. Uncertain. Fuzz. 10, 571-588 (2002
103. Machanavajjhala A, Gehrke J, Kifer D, Venkitasubramaniam M. L-diversity: Privacy beyond k-Anonymity. ACM Trans. Knowl. Discov. Data 1 (2007
104. McGuire AL. Identifiability of DNA data: The need for consistent federal policy. Am. J. Bioethics 8(10), 75-76 (2008
105. Rodriguez LL, Brooks LD, Greenberg JH, Green ED. The complexities of genomic identifiability. Science 339, 275-276 (2013
106. dbGaP: Genotypes and Phenotypes. www.ncbi.nlm.nih.gov/projects/gap/cgi- bin/about.cgi#controlled
107. Kaye J, Heeney C, Hawkins N, De Vries J, Boddington P. Data sharing in genomics-re-shaping scientific practice. Nat. Rev. Genet. 10(5), 331-335 (2009
108. Lunshof J, Chadwick R, Vorhaus D, Church G. From genetic privacy to open consent. Nat. Rev. Genet. 9, 406-411 (2008
109. Manolio T, Chisholm R, Ozenberger B et al. Implementing genomic medicine in the clinic: The future is here. Genet. Med. 258-267 (2013
110. Evans J, Khoury M. The arrival of genomic medicine to the clinic is only the beginning of the journey. Genet. Med. 268-269 (2013
111. National Human Genome Research Institute.www.genome.gov/27554185